News & Updates

Show Multimedia Only

Satralizumab cuts relapse risk in MOGAD

Satralizumab reduces the risk of relapse by 68 percent in adults and adolescents with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), as shown in the phase III METEOROID study presented at AAN 2026.

Satralizumab cuts relapse risk in MOGAD

a day ago

Tirzepatide lowers risk of diabetic retinopathy, complications

03 Jun 2026 by

Treatment with tirzepatide, compared with lifestyle intervention alone, helps prevent the incidence of new or progressive diabetic retinopathy (DR) and its complications among patients with diabetes and overweight or obesity, suggests a study.

Tirzepatide lowers risk of diabetic retinopathy, complications

03 Jun 2026

Corticosteroid-sparing topical treatments safe, efficacious for VKC in children

02 Jun 2026 by

Treatment with corticosteroid-sparing topical interventions such as cyclosporine, tacrolimus, sodium cromoglycate, and interferon alpha-2 demonstrates efficacy in improving the signs and symptoms of vernal keratoconjunctivitis (VKC) in children, as shown in a study.

Corticosteroid-sparing topical treatments safe, efficacious for VKC in children

02 Jun 2026

96-week PULSAR data support aflibercept 8 mg for nAMD

29 May 2026 by

Updated results from the phase III PULSAR trial show that intravitreal (IVT) aflibercept 8 mg, when administered at extended dosing intervals of up to 20 weeks, led to visual gains and anatomic improvements comparable to the 2-mg dose, with no new safety concerns over 96 weeks, in treatment-naïve individuals with neovascular age-related macular degeneration (nAMD).

96-week PULSAR data support aflibercept 8 mg for nAMD

29 May 2026

Can low-dose atropine prevent myopia?

25 May 2026 by

In the ATOM*3 trial, atropine 0.01% did not prevent the onset of myopia in young children with premyopia (SE** +1.00 to −0.49 dioptres [D]) and low myopia (SE −0.50 to −1.50 D), but there was a trend towards less progression with atropine.

Can low-dose atropine prevent myopia?

25 May 2026

Increasing confidence in starting aflibercept 8 mg for nAMD — two HK cases

14 May 2026 by

A 53-year-old female presented on 11 March 2024 with a 2-month history of distorted vision and marked visual impairment in her left eye (OS). Her relevant treatment history included radial keratotomy. Baseline OS visual acuity (VA) was counting fingers.

Increasing confidence in starting aflibercept 8 mg for nAMD — two HK cases

14 May 2026

Tebentafusp a ray of hope in rare eye cancer

11 May 2026 by

The 5-year data from the phase III IMCgp100-202 study demonstrate durable, long-term overall survival (OS) benefit with the novel agent tebentafusp—a first-in-class, bispecific, soluble T-cell receptor (TCR) therapeutic—in individuals with previously untreated metastatic uveal melanoma (UM).

Tebentafusp a ray of hope in rare eye cancer

11 May 2026

PCE predicts ocular diseases using primary care data

07 May 2026

The single composite metric Pooled Cohort Equations (PCE) helps identify the risk for multiple ocular diseases using data readily available in primary care, a study has shown.

PCE predicts ocular diseases using primary care data

07 May 2026

Plasma exchange helps enhance vision in patients with acute optic neuritis

06 May 2026

Plasma exchange (PLEX) appears to improve visual outcomes in acute optic neuritis (ON), reveals a study. Vision loss severity, older age, prior ON in the affected eye, and delay to PLEX tend to contribute to less visual recovery.

Plasma exchange helps enhance vision in patients with acute optic neuritis

06 May 2026

Does semaglutide use raise NAION risk?

06 May 2026

Users of semaglutide do not appear to be at greater risk of developing nonarteritic anterior ischaemic optic neuropathy (NAION), suggests a study.

Does semaglutide use raise NAION risk?

06 May 2026

News & Updates

Showing Ophthalmology articles

Showing

Specialty:

Satralizumab cuts relapse risk in MOGAD

Satralizumab cuts relapse risk in MOGAD

Tirzepatide lowers risk of diabetic retinopathy, complications

Tirzepatide lowers risk of diabetic retinopathy, complications

Corticosteroid-sparing topical treatments safe, efficacious for VKC in children

Corticosteroid-sparing topical treatments safe, efficacious for VKC in children

96-week PULSAR data support aflibercept 8 mg for nAMD

96-week PULSAR data support aflibercept 8 mg for nAMD

Can low-dose atropine prevent myopia?

Can low-dose atropine prevent myopia?

Increasing confidence in starting aflibercept 8 mg for nAMD — two HK cases

Increasing confidence in starting aflibercept 8 mg for nAMD — two HK cases

Tebentafusp a ray of hope in rare eye cancer

Tebentafusp a ray of hope in rare eye cancer

PCE predicts ocular diseases using primary care data

PCE predicts ocular diseases using primary care data

Plasma exchange helps enhance vision in patients with acute optic neuritis

Plasma exchange helps enhance vision in patients with acute optic neuritis

Does semaglutide use raise NAION risk?

Does semaglutide use raise NAION risk?